Sana Biotechnology to present first-in-human hypoimmune islet transplant data at EASD 2026

Sana Biotechnology will present first-in-human clinical data for its UP421 hypoimmune allogeneic islet cell transplant in type 1 diabetes at the EASD 2026 symposium on October 2, 2026. The procedure was conducted without immunosuppression, demonstrating the efficacy of the company's HIP immune-evasion engineering approach.

Sana Biotechnology disclosed first-in-human clinical data from an investigator-sponsored transplant of UP421 hypoimmune allogeneic primary islet cells in type 1 diabetes. * The transplant was performed without any immunosuppression, highlighting the company’s HIP immune-evasion engineering approach. * The data are scheduled for presentation at an EASD 2026 symposium in Milan on Oct. 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010900PRIMZONEFULLFEED9754558) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)